Pharmacology, Toxicology and Pharmaceutical Science
Pharmacokinetics
100%
Malignant Neoplasm
34%
Docetaxel
33%
Breast Cancer
32%
Tamoxifen
31%
Therapeutic Drug Monitoring
30%
Chemotherapy
28%
Endoxifen
26%
Paclitaxel
21%
Non Small Cell Lung Cancer
21%
Overall Survival
20%
Peritoneum Metastasis
19%
Phosphotransferase Inhibitor
19%
Irinotecan
18%
Neoplasm
15%
Erlotinib
14%
Adverse Event
14%
Progression Free Survival
12%
Osimertinib
11%
Nivolumab
11%
Lung Cancer
10%
Intraperitoneal Chemotherapy
10%
Clinical Trial
9%
Solid Malignant Neoplasm
9%
CYP2D6
9%
Sorafenib
8%
Disease
8%
Pazopanib
8%
Actinium 225
8%
Pemetrexed
8%
Alectinib
8%
Duragesic
8%
Nintedanib
8%
Neutropenia
7%
Combination Therapy
7%
Prospective Study
7%
CYP3A4
7%
Ritonavir
6%
Protein Tyrosine Kinase Inhibitor
6%
Bevacizumab
6%
Pharmacodynamics
6%
Monotherapy
6%
Prostate Cancer
6%
Immunotherapy
6%
Oxaliplatin
6%
Sunitinib
6%
Palbociclib
6%
Olaparib
6%
Radioisotope
6%
Taxane
6%
Medicine and Dentistry
Peritoneum Metastasis
16%
Overall Survival
12%
Irinotecan
9%
Intraperitoneal Chemotherapy
9%
Malignant Neoplasm
9%
Tamoxifen
8%
Systematic Review
8%
Therapeutic Drug Monitoring
8%
Nivolumab
8%
Pharmacokinetics
6%
Breast Cancer
6%
Systemic Therapy
5%
Paclitaxel
5%
Meta-Analysis
5%
Neoplasm
5%
Non Small Cell Lung Cancer
5%
Hepatic Arterial Infusion
5%
Colorectal Liver Metastasis
5%
Radionuclide Therapy
5%
Endoxifen
5%